November 2, 2022

Phase 2b results of psilocybin for treatment resistant depression

Results of a phase 2b trial for the use of psilocybin in treatment resistant depression has been published in the New England Journal of Medicine. This is the largest trial of psilocybin for treatment resistant depression to date so is a key step in better understanding how this drug may have a use in this condition. Journalists dialled in to hear from the investigators of the study explain their results and answer any questions.

Speakers included:

Prof Guy Goodwin, Chief Medical Officer, COMPASS Pathways and Emeritus Professor of Psychiatry, University of Oxford

Dr James Rucker, Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust & Senior Clinical Lecturer at King’s College London

Nadav Liam Modlin, Psychology & Psychotherapy Lead in Psychedelics and Therapist Trainer at King’s College London

This Briefing was accompanied by an SMC Roundup of Comments.